Core Viewpoint - Jazz Pharmaceuticals' shares increased nearly 6% following positive results from the phase III IMforte study, which evaluated the combination of Zepzelca and Roche's Tecentriq in treating extensive-stage small cell lung cancer [1][2]. Group 1: Study Results - The IMforte study demonstrated statistically significant improvements in overall survival and progression-free survival for the Zepzelca-Tecentriq combination compared to Tecentriq alone [2]. - The combination therapy was well-tolerated among participants, with no new safety signals reported [2]. Group 2: Regulatory Plans - Jazz Pharmaceuticals plans to submit a regulatory filing in the first half of 2025 for the Zepzelca-Tecentriq combination as a first-line maintenance treatment for extensive-stage small cell lung cancer [3]. - PharmaMar, which licensed Zepzelca to Jazz, also intends to submit a regulatory filing with the EMA for the same combination in the first half of 2025 [4]. Group 3: Current Market Performance - Year-to-date, Jazz Pharmaceuticals' shares have decreased by 4.6%, while the industry has seen a decline of 2.9% [3]. - Jazz's Zepzelca has been under accelerated FDA approval since 2020 for treating adult patients with metastatic small-cell lung cancer previously treated with platinum-based chemotherapy [3]. Group 4: Future Studies - The company is currently conducting the confirmatory phase III LAGOON study to evaluate Zepzelca for patients with relapsed small cell lung cancer, with plans to convert accelerated approval to full approval if results are positive [3].

Group 1 - Investors have not fully recognized the significance of two recent legal victories for Jazz Pharmaceuticals, which are expected to enhance the company's long-term prospects [2] - The first legal win was a partial victory against a competitor, indicating a positive shift in the competitive landscape for Jazz Pharmaceuticals [2] Group 2 - The article emphasizes the importance of tracking attractive risk/reward situations in the biotech sector, suggesting that there are potential growth stocks worth considering [2]

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab. Zanidatamab that belongs to the NSCLC market is estimated to be worth $32 billion. Capturing even a modest 5% share could translate into $1.6 billion in additional revenue for Jazz. Considering the company's 2023 revenue of $3.8 billion, this represents a substantial growth ...

Jazz Pharmaceuticals (JAZZ) focuses on making drugs for neuroscience and oncology. The company derives most of its revenues from its sleep disorder drugs — Xywav and Xyrem. Xywav is a low-sodium formulation of Jazz's legacy drug, Xyrem. It also has a rapidly growing oncology portfolio. Jazz's revenues continue to benefit from strong demand for newer drugs like Xywav, Epidiolex and Rylaze. Jazz has also regularly boosted its commercial portfolio and pipeline through acquisitions. Jazz boasts a promising pipe ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation met ...

Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–estimated overall survival (OS) of 59% at 30 months DUBLIN, Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of ...

New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN, Sept. 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in ...

Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatment on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) DUBLIN, Sept. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present eight abstracts at the 15th European Epilepsy Congress (EEC), including a subgroup analysis of the BECOME (BEhav ...

DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also granted the initial purc ...

DUBLIN, Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $850 million aggregate principal amount of exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities A ...